Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 174

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 174
---
 | December 31, |
|:--------------------------------|:----|:-----|--------------:|:----|:-----|-------------:|
| Cash                            |     | $    |       155,652 |     | $    |    1,550,098 |
| Money market funds              |     |      |         1,004 |     |      |    1,026,318 |
| Total cash and cash equivalents |     | $    |       156,656 |     | $    |    2,576,416 |

Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $ 250,000per institution. The amount in excess of the FDIC insurance as of September 30, 2024 was $ 0. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Marketable Securities

Our investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading of debt securities are charged to income.

The marketable securities held by the Company, which are classified as trading marketable securities, consisted of an outstanding balance of $ 0and $ 2.9million as of September 30, 2024 and December 31, 2023, respectively. During the three months ended September 30, 2024 and 2023, the Company recognized interest income of $ 2,524and $ 20,765, realized gains of $ 56,398and $ 0, and unrealized losses of $ 42,898and unrealized gains of $ 9,606, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized interest income of $ 38,135and $ 56,720, realized gains of $ 100,118and $ 1,744, and unrealized loss of $ 71,568and unrealized gain of $ 21,134, respectively.

Fair Value of Financial Instruments

The Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair Value is defined as the exit price, or